Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 0.85 |
| ▸ | MMP9 | P14780 | 10/20 | 0.85 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.85 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | MMP1 | P03956 | 1/20 | 0.74 |
| ▸ | MMP3 | P08254 | 1/20 | 0.74 |
| ▸ | MMP7 | P09237 | 1/20 | 0.74 |
| ▸ | MMP13 | P45452 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697591 | 1.00 | MMP2 (0.85) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL697592 | 1.00 | MMP2 (0.85) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL6545297 | 0.92 | MMP2 (1.00) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL1920507 | 0.92 | MMP2 (1.00) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL32691761 | 0.92 | MMP2 (1.00) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL8912956 | 0.91 | L3MBTL1 (0.78) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL3009406 | 0.90 | MMP2 (0.92) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL14218255 | 0.90 | MMP2 (0.79) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL8063645 | 0.90 | TDP1 (0.78) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 | |
| SCHEMBL697477 | 0.90 | MMP2 (0.79) | MMP2MMP9ADAMTS4ADAMTS5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897843-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2024-02-13 | — | — | US | disclosed |
| EP-4289819-A2 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatebau e.K. (DE) | 2023-12-13 | — | — | EP | disclosed |
| US-20230008387-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2023-01-12 | — | — | US | disclosed |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2022-10-18 | — | — | US | disclosed |
| EP-3653607-A2 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatenbau e.K. (DE) | 2020-05-20 | — | — | EP | disclosed |
| US-20200087257-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2020-03-19 | — | — | US | disclosed |
| US-10464898-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2019-11-05 | — | — | US | disclosed |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-2958894-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatebau KG (DE) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014128139-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2014-08-28 | — | — | WO | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022782-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PIPERIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-02-11 | — | — | EP | disclosed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | disclosed |
| EP-0796271-B1 | DIPEPTIDE P-AMIDINOBENZYLAMIDES WITH N-TERMINAL SULFONYL OR AMINOSULFONYL RADICALS | BASF AG (DE) | 2000-02-02 | — | — | EP | disclosed |
| WO-1996017860-A1 | NEW DIPEPTIDE P-AMIDINOBENZYLAMIDES WITH N-TERMINAL SULFONYL OR AMINOSULFONYL RADICALS | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | MMP2 1206/4885MMP9 1373/4885ADAMTS4 2548/4885 |
| US-20230008387-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | MMP2 4358/4885MMP9 4567/4885ADAMTS4 4756/4885 |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | MMP2 4358/4885MMP9 4567/4885ADAMTS4 4756/4885 |
| US-11897843-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | MMP2 4338/4885MMP9 4597/4885ADAMTS4 4764/4885 |
| US-20200087257-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | MMP2 4358/4885MMP9 4567/4885ADAMTS4 4756/4885 |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | SNCA, SYNJ1, KCNH2 | MMP2 2580/4885MMP9 2726/4885ADAMTS4 4696/4885 |
| US-10464898-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | MMP2 4285/4885MMP9 4570/4885ADAMTS4 4743/4885 |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | MMP2 4285/4885MMP9 4570/4885ADAMTS4 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.